La Jolla Pharmaceuticals
Executive Summary
Abbott terminates development agreement with firm for lupus drug LJP 394 following assessment of a Phase II/III trial, which showed that the primary endpoint, time to renal flare, did not achieve statistical significance. La Jolla Pharmaceuticals is reducing its staff from 95 to 54, and will focus on pre-clinical development of a drug candidate for antibody-mediated thrombosis